Ibrutinib becomes first approved treatment for rare B-cell lymphoma

Further information
View Imbruvica drug record 
Summary of Product Characteristics
Manufacturer: Janssen Cilag

The Bruton's tyrosine kinase inhibitor ibrutinib (Imbruvica) has been approved for the treatment of patients with Waldenström's macroglobulinaemia.

Imbruvica is indicated in patients with the rare non-Hodgkin's lymphoma who have received at least one prior therapy for the condition, or as first-line treatment for patients unsuitable for chemo-immunotherapy.

Imbruvica was previously licensed only for the treatment of relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukaemia.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases